Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 11:24 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 11,328 matching trials from the live ClinicalTrials.gov search.
Filters: Cleveland, Ohio Clear all
Completed Phase 3 Interventional Results available

Anti-VEGF Treatment for Prevention of PDR/DME

NCT02634333
View directory record Official record
Conditions
Diabetic Retinopathy, Diabetic Macular Edema
Interventions
Prompt Sham, Prompt aflibercept, Deferred laser, Deferred aflibercept
Procedure · Drug
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years and older
Enrollment
399 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
81
States / cities
Phoenix, Arizona • Tucson, Arizona • Huntington Beach, California + 68 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2023 · Synced Nov 3, 2026, 11:24 AM EST
Completed No phase listed Observational

S9007, Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers

NCT00996047
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
cytogenetic analysis, fluorescence in situ hybridization
Genetic
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Not listed
Enrollment
3,341 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1991 – 2012
U.S. locations
280
States / cities
Mobile, Alabama • Anchorage, Alaska • Tucson, Arizona + 182 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2015 · Synced Nov 3, 2026, 11:24 AM EST
Completed Not applicable Interventional

Rehabilitation Enhanced by Partial Arterial Inflow Restrictions

NCT02746458
View directory record Official record
Conditions
Closed Femur Fracture
Interventions
Blood Flow Restriction, Delfi PTSII Tourniquet System
Other · Device
Lead sponsor
Major Extremity Trauma Research Consortium
Other
Eligibility
18 Years to 55 Years
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
8
States / cities
Indianapolis, Indiana • Baltimore, Maryland • Bethesda, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Nov 3, 2026, 11:24 AM EST
Terminated Phase 3 Interventional

ASA404 or Placebo in Combination With Paclitaxel and Carboplatin as First-Line Treatment for Stage IIIb/IV Non-Small Cell Lung Cancer

NCT00662597
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
ASA404, Placebo, carboplatin, Paclitaxel
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
100
States / cities
Mobile, Alabama • Tucson, Arizona • Bentonville, Arkansas + 86 more
Source: ClinicalTrials.gov public record
Updated Dec 24, 2020 · Synced Nov 3, 2026, 11:24 AM EST
Completed Phase 3 Interventional Results available

Expanded Access Program for Maraviroc At Multiple Centers

NCT00426660
View directory record Official record
Conditions
HIV Infections
Interventions
maraviroc
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
16 Years and older
Enrollment
1,047 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
190
States / cities
Birmingham, Alabama • Hobson City, Alabama • Tucson, Arizona + 113 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2016 · Synced Nov 3, 2026, 11:24 AM EST
Completed Phase 2 Interventional

Humanized Anti-IL-2 Receptor Monoclonal Antibody in Moderate-to-severe Ulcerative Colitis

NCT00073047
View directory record Official record
Conditions
Ulcerative Colitis, Gastrointestinal Disease, Inflammatory Bowel Disease
Interventions
Daclizumab
Drug
Lead sponsor
Facet Biotech
Industry
Eligibility
12 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
30
States / cities
Huntsville, Alabama • Anaheim, California • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2009 · Synced Nov 3, 2026, 11:24 AM EST
Completed No phase listed Observational Accepts healthy volunteers

Prevalence of Chronic Airway Obstruction in Subjects With a History of Cigarette Smoking in a Primary Care Setting

NCT01013948
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Non-Interventional
Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
30 Years to 87 Years
Enrollment
1,574 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
40
States / cities
Adamsville, Alabama • Foothill Ranch, California • Huntington Beach, California + 37 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2012 · Synced Nov 3, 2026, 11:24 AM EST
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Infants

NCT00474526
View directory record Official record
Conditions
Meningitis, Meningococcal
Interventions
Meningococcal ACWY Conjugate Vaccine, DTaP-IPV-HBV, Hib, Rotavirus, Pneumococcal 7-valent Conjugate Vaccine, HAV, MMR-V, DTaP
Biological
Lead sponsor
Novartis Vaccines
Industry
Eligibility
2 Months to 2 Months
Enrollment
4,545 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
53
States / cities
Bessemer, Alabama • Birmingham, Alabama • Downey, California + 43 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2014 · Synced Nov 3, 2026, 11:24 AM EST
Completed Not applicable Interventional Results available

Atrium iCAST Iliac Stent Pivotal Study

NCT00593385
View directory record Official record
Conditions
Peripheral Vascular Disease
Interventions
iCAST covered stent
Device
Lead sponsor
Atrium Medical Corporation
Industry
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
24
States / cities
Little Rock, Arkansas • Mountain View, California • Sacramento, California + 19 more
Source: ClinicalTrials.gov public record
Updated May 17, 2018 · Synced Nov 3, 2026, 11:24 AM EST
Terminated Phase 2 Interventional Results available

Efficacy and Safety of LBH589B in Adult Patients With Multiple Myeloma

NCT00445068
View directory record Official record
Conditions
Multiple Myeloma
Interventions
LBH589
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
24
States / cities
Scottsdale, Arizona • Berkeley, California • Duarte, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2021 · Synced Nov 3, 2026, 11:24 AM EST
Terminated Phase 2 Interventional

A Multicenter, Double Blind, Placebo-Controlled, Safety and Tolerability Study of BMS-708163 in Patients With Prodromal Alzheimer's Disease

NCT00890890
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Avagacestat, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
45 Years to 90 Years
Enrollment
263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
50
States / cities
Birmingham, Alabama • Peoria, Arizona • Phoenix, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2015 · Synced Nov 3, 2026, 11:24 AM EST
Recruiting Phase 1 Interventional

SW-682 in Advanced Solid Tumors

NCT06251310
View directory record Official record
Conditions
Advanced Solid Tumor, Mesothelioma, Malignant
Interventions
SW-682, Combination Therapy
Drug
Lead sponsor
SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
Industry
Eligibility
18 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
8
States / cities
Scottsdale, Arizona • Los Angeles, California • Sacramento, California + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Nov 3, 2026, 11:24 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Handheld Mirror to Improve Child's Behavior During Dental Treatment

NCT02366520
View directory record Official record
Conditions
Behavior
Interventions
handheld mirror
Device
Lead sponsor
Case Western Reserve University
Other
Eligibility
3 Years to 17 Years
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2021
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 25, 2022 · Synced Nov 3, 2026, 11:24 AM EST
Recruiting Phase 3 Interventional

Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)

NCT05943535
View directory record Official record
Conditions
Progressive Pulmonary Fibrosis, Interstitial Lung Disease
Interventions
Placebo, Inhaled Treprostinil, Treprostinil Ultrasonic Nebulizer
Drug · Device
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
698 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
74
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 60 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Nov 3, 2026, 11:24 AM EST
Recruiting Not applicable Interventional

Deep Brain Stimulation Neural Recordings of Varied Stimulation During Sleep in Parkinson's Disease

NCT07110376
View directory record Official record
Conditions
Parkinson Disease
Interventions
Nighttime Deep Brain Stimulation with Varying Amplitude Settings
Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Nov 3, 2026, 11:24 AM EST
Completed Not applicable Interventional

The Role of the Robotic Platform in Inguinal Hernia Repair Surgery

NCT02816658
View directory record Official record
Conditions
Hernia, Inguinal
Interventions
Laparoscopic Inguinal Hernia Repair, Robotic Inguinal Hernia Repair
Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
21 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
6
States / cities
St Louis, Missouri • New York, New York • Wilmington, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2022 · Synced Nov 3, 2026, 11:24 AM EST
Completed Phase 3 Interventional

Demonstrate Exubera Works As Well As Avandia When Added To Sulfonylurea + Metformin In Controlling Glucose

NCT00150410
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Inhaled insulin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 80 Years
Enrollment
626 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
88
States / cities
Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 72 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2008 · Synced Nov 3, 2026, 11:24 AM EST
Completed Phase 2 Interventional Results available

Study Evaluating Desvenlafaxine Succinate Sustained-Release Tablets (DVS SR) In The Treatment Of Child and Adolescent Outpatients With Major Depressive Disorder

NCT00669110
View directory record Official record
Conditions
Depressive Disorder, Major Depressive Disorder
Interventions
Desvenlafaxine Succinate Sustained-Release Tablets (DVS SR)
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
7 Years to 18 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
9
States / cities
Little Rock, Arkansas • North Miami, Florida • Terre Haute, Indiana + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2021 · Synced Nov 3, 2026, 11:24 AM EST
Enrolling by invitation Not applicable Interventional

Evaluation of the GORE® Ascending Stent Graft

NCT05800743
View directory record Official record
Conditions
Aortic Aneurysm, Thoracic, Pseudoaneurysm, Aortic Dissection, Aorta; Lesion
Interventions
GORE® Ascending Stent Graft (ASG device), GORE® Thoracic Aortic Graft Thoracic Branch Endoprosthesis (TBE Device), Surgery
Device · Procedure
Lead sponsor
W.L.Gore & Associates
Industry
Eligibility
18 Years and older
Enrollment
370 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2034
U.S. locations
41
States / cities
Birmingham, Alabama • Long Beach, California • Los Angeles, California + 37 more
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Nov 3, 2026, 11:24 AM EST
Completed Phase 2 Interventional

A Study of 3 Doses of Dextofisopam in Females With Irritable Bowel Syndrome

NCT00486876
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Dextofisopam
Drug
Lead sponsor
Pharmos
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
324 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
79
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 67 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2011 · Synced Nov 3, 2026, 11:24 AM EST
Completed Phase 4 Interventional Results available

Study to Evaluate Symptoms of Exocrine Pancreatic Insufficiency in Adult Participants With Cystic Fibrosis or Chronic Pancreatitis Treated With Creon

NCT05069597
View directory record Official record
Conditions
Cystic Fibrosis, Chronic Pancreatitis
Interventions
CREON
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
21
States / cities
Mobile, Alabama • Madera, California • Gainesville, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2024 · Synced Nov 3, 2026, 11:24 AM EST
Recruiting Phase 3 Interventional

A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

NCT07361497
View directory record Official record
Conditions
Non-small Cell Lung Cancer (NSCLC)
Interventions
Pumitamig, Durvalumab
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
850 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2034
U.S. locations
38
States / cities
Daphne, Alabama • Golden, Colorado • Newark, Delaware + 32 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Nov 3, 2026, 11:24 AM EST
Completed Phase 1 Interventional

Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer)

NCT00085358
View directory record Official record
Conditions
Brenner Tumor, Fallopian Tube Cancer, Ovarian Carcinosarcoma, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mixed Epithelial Carcinoma, Ovarian Mucinous Cystadenocarcinoma, Ovarian Serous Cystadenocarcinoma, Ovarian Undifferentiated Adenocarcinoma, Primary Peritoneal Cavity Cancer, Stage II Ovarian Epithelial Cancer, Stage III Ovarian Epithelial Cancer, Stage IV Ovarian Epithelial Cancer
Interventions
carboplatin, paclitaxel, docetaxel, bevacizumab
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
16
States / cities
Orange, California • Aurora, Colorado • Chicago, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2019 · Synced Nov 3, 2026, 11:24 AM EST
Completed Phase 4 Interventional

ABRIDGE: Low Molecular Weight Heparin in Bridging Patients After Mechanical Valve Replacement

NCT00298285
View directory record Official record
Conditions
Mechanical Valve Replacement, Warfarin Therapy
Interventions
enoxaparin
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2006
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 9, 2007 · Synced Nov 3, 2026, 11:24 AM EST